2022-RA-1134-ESGO First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort

Abstract

initial literature search identified 1815 papers; four met the eligibility criteria. Three were randomized clinical trials and one was a phase II single-arm prospective cohort study. MEKi investigated included: pimasertib, selumetinib, trametinib, and binimetinib. A total of 680 patients were included in these studies, of which 416 were treated with a MEKi alone. All patients were treated for recurrent LGSOC. Objective response rates (ORR) to MEKi ranged from 12.1 to 26% and median progression-free survival (PFS) ranged from 7.2 to 13 months. Conclusion While one study demonstrated significantly improved efficacy of a MEKi over physician-choice systemic therapy in the treatment of recurrent LGSC, another did not show significant benefit. Two additional studies did not compare MEKi to current traditional chemotherapy or hormonal therapies used in the management of LGSC, limiting their clinical relevance. Mutation profiles within the tumors may affect the ORR to various MEKi. Further prospective and randomized trials are needed to determine the efficacy of MEKi in treating LGSC.